{
    "clinical_study": {
        "@rank": "31793", 
        "arm_group": [
            {
                "arm_group_label": "Heart Failure", 
                "arm_group_type": "Other", 
                "description": "adenosine triphosphate, lactate, and protons with phosphate buffer"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "adenosine triphosphate, lactate, and protons with phosphate buffer"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to find out more about the mechanism by which neural feedback\n      from the working muscle affects the development of central fatigue during exercise."
        }, 
        "brief_title": "Muscle Afferent Feedback Effects in Patients With Heart Failure: The Development of Central Fatigue", 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Heart Failure Inclusion Criteria:\n\n          -  Subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, greater\n             than 1 year duration, ages 20-79 years)\n\n          -  New York Heart Association class I through IV symptoms\n\n          -  Left ventricular ejection fraction less than 35 percent (heart failure patients with\n             reduced left ventricular ejection fraction) or greater than 50 percent (heart failure\n             patients with preserved left ventricular ejection fraction)\n\n          -  Sedentary, no regular physical activity for at least 6 months prior\n\n          -  Post-menopausal for at least 2 years and follicle stimulating hormone greater than 40\n\n        Heart Failure Exclusion Criteria:\n\n          -  Patients with atrial fibrillation or heart failure believed to be secondary to atrial\n             fibrillation\n\n          -  Morbidly obese patients with a body mass index greater than 35\n\n          -  Patients with uncontrolled hypertension, greater than 160/100\n\n          -  Anemia with a hemoglobin less than 9\n\n          -  Severe renal insufficiency (creatinine clearance less than 30 by the Cockcroft-Gault\n             formula)\n\n          -  Patients with significant non-cardiac comorbidities\n\n          -  Orthopedic limitations that would prohibit them from performing the elbow-flexor\n             exercise\n\n          -  Current smoker or smoking history of 15 packs or more per year\n\n          -  Women currently taking hormone replacement therapy\n\n        Healthy Control Inclusion Criteria:\n\n          -  Ages 20-75 years\n\n          -  Sedentary, no regular physical activity for at least 6 months prior\n\n          -  Post-menopausal for at least 2 years and follicle stimulating hormone greater than 40\n\n        Healthy Control Exclusion Criteria:\n\n          -  History of cardiovascular related abnormalities or pulmonary abnormalities\n\n          -  Morbidly obese patients with a body mass index greater than 35\n\n          -  Patients with uncontrolled hypertension, greater than 160/100\n\n          -  Anemia with a hemoglobin less than 9\n\n          -  Orthopedic limitations that would prohibit them from performing the elbow-flexor\n             exercise\n\n          -  Current smoker or smoking history of 15 packs or more per year\n\n          -  Women currently taking hormone replacement therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919918", 
            "org_study_id": "62914"
        }, 
        "intervention": {
            "arm_group_label": [
                "Heart Failure", 
                "Control"
            ], 
            "intervention_name": "Metabolite Soup", 
            "intervention_type": "Drug", 
            "other_name": "It is a combination fo the following metabolites given at once; adenosine triphosphate, lactate, and protons with phosphate buffer"
        }, 
        "intervention_browse": {
            "mesh_term": "Adenosine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "amy.rogers@hsc.utah.edu", 
                    "last_name": "Amy Rogers, MSPH", 
                    "phone": "801-582-1565", 
                    "phone_ext": "1495"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84148"
                    }, 
                    "name": "Veterans Affairs Salt Lake City Heath Care System"
                }, 
                "investigator": {
                    "last_name": "Markus Amann, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "amy.rogers@hsc.utah.edu", 
                    "last_name": "Amy Rogers", 
                    "phone": "801-582-1565", 
                    "phone_ext": "1495"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84148"
                    }, 
                    "name": "George E Wahlen Vetern Affairs Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_contact": {
            "email": "amy.rogers@hsc.utah.edu", 
            "last_name": "Amy Rogers, MSPH", 
            "phone": "801-582-1565", 
            "phone_ext": "1495"
        }, 
        "overall_official": {
            "affiliation": "University of Utah", 
            "last_name": "Markus Amann, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Elbow Flexor Maximal Voluntary Contraction in newton-meters", 
            "safety_issue": "No", 
            "time_frame": "2 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919918"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}